Concomitant Enalapril and Spironolactone-Induced Hyperkalemia in a Pediatric Patient

Area of Science:

• Pediatric Cardiology
• Pharmacology
• Nephrology

Background:

• Spironolactone, a potassium-sparing diuretic, is used in pediatric heart failure management.
• Limited data exists on the safety and efficacy of spironolactone in infants.
• Standard pediatric heart failure treatment often includes ACE inhibitors.

Purpose of the Study:

• To report a case of hyperkalemia in an infant receiving spironolactone and an ACE inhibitor.
• To highlight the potential risks of concomitant use of these medications in pediatrics.
• To describe the management and resolution of drug-induced hyperkalemia.

Main Methods:

• Case report of a 2-month-old female infant with congestive heart failure.
• Initiation of enalapril (an ACE inhibitor) and spironolactone.
• Monitoring of serum potassium levels and clinical presentation.

Main Results:

• The patient developed severe hyperkalemia (8.9 mEq/L) on day 7 of treatment.
• Hyperkalemia persisted despite dose adjustments of spironolactone.
• Discontinuation of spironolactone led to resolution of hyperkalemia within 72 hours.

Conclusions:

• Concomitant administration of spironolactone and ACE inhibitors may lead to hyperkalemia in pediatric patients.
• Spironolactone discontinuation is an effective intervention for resolving this adverse effect.
• Further research is needed on the safe use of these agents in pediatric populations.